Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

BACKGROUND: Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple sclerosis. We investigated the impact of natalizumab on patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Judith J, Kern, David M, Agarwal, Sonalee S, Zeidman, Ruth, Rajagopalan, Krithika, Kamat, Siddhesh A, Foley, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543243/
https://www.ncbi.nlm.nih.gov/pubmed/23270428
http://dx.doi.org/10.1186/1477-7525-10-155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543243/
https://www.ncbi.nlm.nih.gov/pubmed/23270428
http://dx.doi.org/10.1186/1477-7525-10-155

Ejemplares similares